hydroxychloroquine has been researched along with oligonucleotides in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Bermas, BL; Ermann, J | 1 |
Diamond, B; Yildirim-Toruner, C | 1 |
Chin, TM; Lee, JZ; Leow, YN; Lim, B; Lim, EH; Lim, EK; Lim, PX; Lim, WT; Lunny, DP; Malusay, SR; Nga, ME; Pang, YH; Shyh-Chang, N; Soo, RA; Sun, LL; Tai, BC; Tam, WL; Tan, BJ; Tan, DS; Tan, EH; Yang, H; Zhang, WC | 1 |
Adams, D; Attarian, S; Cintas, P; Desguerre, I; Laforet, P; Molon, A; Pereon, Y; Pisella, LI; Salort-Campana, E; Solé, G; Stojkovic, T; Tiffreau, V; Wahbi, K | 1 |
2 review(s) available for hydroxychloroquine and oligonucleotides
Article | Year |
---|---|
The biology behind the new therapies for SLE.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens; Autoantibodies; B-Lymphocytes; Cytokines; Humans; Hydroxychloroquine; Immunity, Cellular; Immunologic Factors; Immunosuppressive Agents; Interferon-alpha; Lupus Erythematosus, Systemic; Mycophenolic Acid; Oligonucleotides; Rituximab; Toll-Like Receptors | 2007 |
Current and novel therapeutics in the treatment of systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Cyclophosphamide; Humans; Hydroxychloroquine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulins, Intravenous; Lupus Erythematosus, Systemic; Mycophenolic Acid; Oligonucleotides; Rituximab | 2011 |
2 other study(ies) available for hydroxychloroquine and oligonucleotides
Article | Year |
---|---|
Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Hydroxychloroquine; Lung Neoplasms; Lymphatic Metastasis; Mice; MicroRNAs; Neoplastic Stem Cells; Oligonucleotides; Quinazolines; Signal Transduction; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.
Topics: alpha-Glucosidases; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Bacterial Agents; Antimalarials; Azithromycin; Betacoronavirus; Cardiorespiratory Fitness; Coronavirus Infections; COVID-19; Emergency Treatment; France; Glycogen Storage Disease Type II; Hospitalization; Humans; Hydroxychloroquine; Immune System Diseases; Immunoglobulins, Intravenous; Immunosuppressive Agents; Muscular Atrophy, Spinal; Neuromuscular Diseases; Oligonucleotides; Pandemics; Physical Therapy Modalities; Pneumonia, Viral; Prognosis; RNA, Small Interfering; SARS-CoV-2; Steroids; Withholding Treatment | 2020 |